RemedyRepack Recalls Amlodipine/Valsartan/HCTZ Tablets Due to NDMA Contamination
RemedyRepack Inc. is recalling Amlodipine/Valsartan/HCTZ tablets in South Carolina due to trace amounts of NDMA, a possible impurity.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text explicitly states the agency classification is Class II. Per the rubric, if the agency's own classification is FDA Class I or USDA Class I, the score is never below 4. Since this is FDA Class II, it maps to the 'Severe' category (Score 4) in the provided rubric structure where Class II is grouped with Severe criteria.
Plain-English summary
RemedyRepack Inc. is recalling Amlodipine/Valsartan/HCTZ 10mg/320mg/25mg tablets (NDC #70518-1220-0) manufactured by Torrent Pharma LTD. The recall involves 3 bottles of 90 tablets (270 tablets overall) distributed in South Carolina. The specific lot number is B0476653-080218 with an expiration date of 08/2019.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations involving the detection of trace amounts of NDMA, a possible impurity or contaminant, in an active pharmaceutical ingredient. The FDA has classified this recall as Class II.
Consumers who have this specific product should stop using it and contact their healthcare provider or pharmacist for guidance on alternative treatment options.
The recalled product
- Product
- Amlodipine/Valsartan/HCTZ 10mg/320mg/25mg Tablet, Rx Only (HDPE 90cc Bottles in cardboard trays) MFG Torrent Pharma LTD, Indrad, India 38272, NDC #70518-1220-0
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- 70518-1220-0
- Lot #: B0476653-080218
- Exp. Date: 08/2019
Distribution
Distributed in 1 state:
Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · ndma contamination
See all →- SevereMetformin Hydrochloride Extended-Release Tablets Recalled for NDMA Contamination
FDA (Drugs) · 2022-02-02
- ModerateMetformin 750 mg Extended Release Recalled for NDMA Contamination
FDA (Drugs) · 2022-01-19
- HighMetformin Hydrochloride Tablets Recalled for NDMA Contamination
FDA (Drugs) · 2021-06-30
- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-11-25
- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-07-08
Similar recalls
- SevereRemedyRepack Recalls Amlodipine/Valsartan HCTZ Tablets Due to NDMA Contamination
FDA (Drugs) · 2018-10-31
- SevereRemedyRepack Recalls Valsartan/HCTZ Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-08-08
- SevereTorrent Pharma Recalls Amlodipine, Valsartan, and Hydrochlorothiazide Tablets Due to Impurity
FDA (Drugs) · 2018-09-05
- SevereTorrent Pharma Recalls Amlodipine, Valsartan, and Hydrochlorothiazide Tablets
FDA (Drugs) · 2018-09-05
- SevereLosartan Potassium/HCTZ Tablets Recalled for Nitrosamine Impurity
FDA (Drugs) · 2019-05-08
- HighLosartan HCTZ tablets recalled for manufacturing impurity levels above acceptable limits
FDA (Drugs) · 2022-06-01